Asuragen, Illumina Partner
News Sep 10, 2015
Asuragen will leverage its Quantidex™ NGS product platform for development of customized companion diagnostics for its biotech and pharma partners on the Illumina MiSeqDx™ instrument. Asuragen’s recently launched Quantidex™ Pan Cancer Kit* demonstrates its optimized NGS system that unifies pre-analytical DNA QC, sample quantification, multiplex PCR enrichment, dual-index barcoding, and library purification and quantification, using reagents provided in a single kit. In addition, it integrates Asuragen’s analytics and reporting suite, the Quantidex™ Reporter, providing a straight forward sample-to-answer solution for Asuragen NGS panels.
“We are uniquely positioned to be a nimble and high quality companion diagnostic partner to biotech and pharma”, said Matt McManus, President and CEO of Asuragen. “Sequencing-based companion diagnostic projects benefit from our established Quantidex™ NGS product platform, which allows for rapid and efficient development of a unique DNA and/or RNA panel of interest. The Quantidex™ NGS system is built under design control and manufactured in our cGMP facility, providing a high quality basis for regulated diagnostic product development.”
Back in 2009, researchers identified a herd of Awassi sheep suffering from "day blindness". As that term implies, these sheep were blind during the day (in bright light) but could see at night, in low-light conditions. After identifying the genetic basis of this blindness, researchers have now successfully used gene therapy to restore their daytime vision.READ MORE